The Role of HER2 in CRC

Opinion
Video

Drs Cohen, Wu, and Ahn discuss HER2 in colorectal cancer, explaining that increased expression indicates possible benefit from HER2 inhibitors; Ahn summarized studies showing modest activity of dual HER2 inhibition compared to single agent trastuzumab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Expert Perspectives: Tazemetostat in R/R FL
      Expert Perspectives: Tazemetostat in R/R FL
      Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
      Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
      4 experts in this video
      Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
      4 experts in this video
      Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
      A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
      A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
      Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
      Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
      Addressing Critical Unmet Needs in ES-SCLC Patient Management
      Addressing Critical Unmet Needs in ES-SCLC Patient Management
      Clinical Scenario: A 73-Year-Old Patient With R/R FL Requires Treatment in the Third-Line Setting
      Clinical Scenario: A 73-Year-Old Patient With R/R FL Requires Treatment in the Third-Line Setting
      Aligning Treatment Goals in R/R FL: Physician vs Patient Perspectives
      Aligning Treatment Goals in R/R FL: Physician vs Patient Perspectives
      Related Content
      Sotorasib at 960 mg Plus Panitumumab Emerges as SOC in KRAS G12C+ mCRC

      Sotorasib at 960 mg Plus Panitumumab Emerges as SOC in KRAS G12C+ mCRC

      Tim Cortese
      May 1st 2025
      Article

      Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years and older.

      Pancreatic/Colorectal Adenocarcinoma Rates Have Increased in Young Adults

      Roman Fabbricatore
      April 15th 2025
      Article

      Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

      Jagoda Misniakiewicz, PharmD
      June 10th 2024
      Podcast

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

      FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

      Tim Cortese
      April 8th 2025
      Article

      The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      Tim Cortese
      March 31st 2025
      Article

      Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.